HCA Healthcare, Inc. Investigated by the Portnoy Law Firm

The Portnoy Law Firm advises HCA Healthcare, Inc. (“HCA" or the "Company") (NYSE: HCA) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

On July 14, 2026, HCA Healthcare published a press release outlining its preliminary operational and financial performance for the second quarter of 2026. Within the release, the enterprise significantly downgraded its full-year 2026 earnings outlook, attributing the reduction to an adverse shift in its payer breakdown. This trend was spurred by a surge in uninsured patient visits—largely stemming from individuals losing coverage through health insurance marketplaces—which erased roughly $400 million in quarterly revenue.

Consequently, HCA revised its full-year earnings forecast downward to a range of $28.70 to $30.50 per share, while tightening its revenue guidance to between $77 billion and $79.5 billion (compared to its previous projection of $76.5 billion to $80 billion). Adjusted EBITDA expectations were also scaled back to $15.4 billion–$16.1 billion, down from the prior target of $15.55 billion–$16.45 billion.

Following these disclosures, HCA Healthcare’s equity value dropped by $27.14 per share, or 6.95%, settling at $363.60 at the close of trading on July 14, 2026.